Latest Biotech News

ICON partnered with Advarra to build an integrated, AI-driven site network aimed at reducing trial startup delays and easing operational bottlenecks. The collaboration connects ICON’s trial...

Eli Lilly expanded its AI drug discovery strategy through a multibillion-dollar deal with Insilico Medicine. The company will pay $115 million upfront, with up to $2.75 billion in milestone...

Data at the 2026 American Academy of Dermatology meeting pointed to intensified competition in atopic dermatitis as targeted oral therapies move closer to challenging injected biologics. The...

Kailera Therapeutics filed for an IPO to fund its obesity pipeline, spotlighting ribupatide, a weekly GLP-1/GIP agonist in late-stage development. The company said ribupatide delivered about 18%...

Takeda announced additional workforce reductions, starting with nearly 250 Cambridge-area employees as part of a broader cost-saving plan. A state filing stated layoffs begin in July, though some...

The U.S. FDA is considering how to handle its National Priority Voucher (CNPV) program after its introduction last year. The provided material says the program aims to create an ultrafast review...

Karolinska Institutet, Karolinska University Hospital, and SciLifeLab integrated whole genome sequencing into routine rare-disease diagnostics at Karolinska University Hospital. The initiative...

Researchers reported the completion of the first-ever clinical trial using nuclease-free, homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia (MMA)....

Eli Lilly’s investigational co-packaged regimen avutometinib plus defactinib (Avmapki/Fakzynja) won FDA approval for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)...

Eli Lilly is expanding its AI drug discovery footprint through a multibillion-dollar commercialization and development deal with Insilico Medicine. Under terms disclosed by Insilico, Lilly will...

Viridian Therapeutics’ elegrobart (VRDN-003) trial results for active thyroid eye disease drove sharp investor reaction after a pivotal Phase 3 readout showed proptosis improvements but renewed...

Otsuka is moving deeper into neuroplastogen approaches for PTSD via a planned acquisition of Transcend Therapeutics for $1.22 billion. The deal, announced by Otsuka, expands Otsuka’s neuroscience...

Rocket Pharmaceuticals received FDA approval for Kresladi (gene therapy) for leukocyte-adhesion deficiency type 1 (LAD-1), an ultra-rare, potentially fatal inherited immunodeficiency in infants...

ICON is teaming with Advarra to build an integrated, AI-driven site network model aimed at reducing clinical trial startup delays and operational bottlenecks. The collaboration connects ICON’s...

Blackstone closed its largest life sciences private fund on record, raising $6.3 billion for the Blackstone Life Sciences platform (BXLS). The fund is nearly 40% larger than the firm’s prior $4.6...

Roche received U.S. FDA 510(k) clearance for Cobas lab automation units and also gained CE marking for a multiplex blood donor screening assay. The automation modules (Cobas c 703 and Cobas ISE...

Kailera Therapeutics filed for an IPO to fund late-stage development of its obesity portfolio led by ribupatide, a weekly GLP-1/GIP agonist in Phase 3. The filing positions the company to compete...

Researchers reported preclinical progress on engineered immune cell engagers (ICEs) designed to better coordinate activating and inhibitory signals within macrophages for solid tumor clearance. In...

Eli Lilly expanded its AI-driven drug discovery push by signing an agreement with Insilico Medicine to develop and commercialize preclinical oral therapeutics across multiple therapeutic areas....

The FDA approved avutometinib and defactinib as a co-packaged oral combination for adults with KRAS-mutated recurrent LGSOC after prior systemic therapy. The approval is positioned as a rare...